Article Text

Download PDFPDF
Original article
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
  1. Silvio Danese1,
  2. Janusz Rudziński2,
  3. Wolfgang Brandt3,
  4. Jean-Louis Dupas4,
  5. Laurent Peyrin-Biroulet5,
  6. Yoram Bouhnik6,
  7. Dariusz Kleczkowski7,
  8. Peter Uebel8,
  9. Milan Lukas9,
  10. Mikael Knutsson10,
  11. Fredrik Erlandsson10,
  12. Mark Berner Hansen10,
  13. Satish Keshav11
  1. 1Istituto Clinico Humanitas, Milan, Italy
  2. 210 Wojskowy Szpital Kliniczny z Polikliniką, Bydgoszcz, Poland
  3. 3Facharzt für Innere Medizin, Potsdam, Germany
  4. 4Centre Hospitalier Universitaire, Amiens, France
  5. 5Inserm U954 and Department of Gastroenterology, Université de Lorraine, Vandœuvre-lès-Nancy, France
  6. 6Hôpital Beaujon, Paris, France
  7. 7Endoskopia Sp. z o. o., Sopot, Poland
  8. 8P. Uebel Haus der Gesundheit, Ludwigshafen, Germany
  9. 9IBD Clinical and Research Centre, ISCARE Lighthouse and 1st Medical Faculty, Charles University, Prague, Czech Republic
  10. 10AstraZeneca R&D, Mölndal, Sweden
  11. 11Department of Medicine, John Radcliffe Hospital, Oxford, UK
  1. Correspondence to Dr Silvio Danese, Department of Gastroenterology, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan 20089, Italy; sdanese{at}


Objective Interleukin-13 (IL-13) has been implicated as a key driver of UC. This trial evaluates the efficacy and safety of tralokinumab, an IL-13-neutralising antibody, as add-on therapy in adults with moderate-to-severe UC despite standard treatments.

Design Non-hospitalised adults with UC (total Mayo score ≥6) were randomised to receive tralokinumab 300 mg or placebo subcutaneously every 2 weeks for 12 weeks. The primary end point was the rate of clinical response at week 8. Secondary efficacy end points included clinical remission and mucosal healing rates at week 8 and changes in total Mayo score, total modified Riley score, partial Mayo score and disease activity markers.

Results Clinical response rate was 38% (21/56) for tralokinumab vs 33% (18/55) for placebo (p=0.406). Clinical remission rate was 18% (10/56) vs 6% (3/55) (p=0.033) and mucosal healing rate was 32% (18/56) vs 20% (11/55) (p=0.104) for tralokinumab vs placebo. Changes to week 8 in total Mayo score and total modified Riley score were similar for tralokinumab and placebo (least-squares mean difference between groups: −0.49 (p=0.394) and 0.25 (p=0.449), respectively). Partial Mayo score at week 4 was lower with tralokinumab than placebo (least-squares mean difference between groups: −0.90 (p=0.041)). No consistent patterns were observed for disease activity markers. Tralokinumab had an acceptable safety profile.

Conclusions Add-on therapy with tralokinumab did not significantly improve clinical response. However, the higher clinical remission rate with tralokinumab than placebo suggests that tralokinumab may benefit some patients with UC. Tralokinumab was well tolerated.

Trial registration number number: NCT01482884.


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.